hCAI/II-IN-5

hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Carbonic Anhydrase

Research Areas >> Metabolic Disease

Research Areas >> Neurological Disease

Signaling Pathways >> Neuronal Signaling >> AChE

IC50: 37.88 ± 0.9956 nM (hCA II), 45.23 ± 0.9684 nM (hCA I), 48.98 ± 0.9407 nM (α-GLY), 420.14 ± 0.9759 nM (AChE); KI: 40.35 ± 5.74 nM (hCA II), 50.04 ± 5.76 nM (α-GLY), 51.67 ± 4.76 nM (hCA I), 363.96 ± 32.87 nM (AChE)[1]

[1]. Lolak N, et al. Synthesis, characterization, inhibition effects, and molecular docking studies as acetylcholinesterase, α-glycosidase, and carbonic anhydrase inhibitors of novel benzenesulfonamides incorporating 1,3,5-triazine structural motifs. Bioorg Chem. 2020 Jul;100:103897.